Home Aminos (2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

(2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

CAS No.:
121032-29-9
Catalog Number:
AG00HFV3
Molecular Formula:
C11H15N5O5
Molecular Weight:
297.2673
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
In Stock USA
United States
$156
- +
100mg
97%
In Stock USA
United States
$225
- +
250mg
97%
In Stock USA
United States
$400
- +
1g
97%
In Stock USA
United States
$1050
- +
Product Description
Catalog Number:
AG00HFV3
Chemical Name:
(2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
CAS Number:
121032-29-9
Molecular Formula:
C11H15N5O5
Molecular Weight:
297.2673
MDL Number:
MFCD00871078
IUPAC Name:
(2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
InChI:
InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
InChI Key:
IXOXBSCIXZEQEQ-UHTZMRCNSA-N
SMILES:
OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1nc(N)nc2OC
UNII:
60158CV180
NSC Number:
755985
Properties
Complexity:
377  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
4  
Defined Bond Stereocenter Count:
0
Exact Mass:
297.107g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
297.271g/mol
Monoisotopic Mass:
297.107g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
149A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.7  
Literature
Title Journal
Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20150801
Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120801
Novel and emerging drugs for rarer chronic lymphoid leukaemias. Current cancer drug targets 20120601
Treatment of acute lymphoblastic leukemia in adults. Critical reviews in oncology/hematology 20120101
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. Clinical Medicine Insights. Oncology 20120101
Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Current pharmaceutical design 20120101
Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism. PloS one 20120101
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology 20111201
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 20110929
Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder. Hematology reports 20110831
In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood 20110825
[Novel conventional therapies in onco-hemathology]. Bulletin du cancer 20110801
Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL. [Rinsho ketsueki] The Japanese journal of clinical hematology 20110601
Educational paper. The development of new therapies for pediatric oncology. European journal of pediatrics 20110501
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. European journal of nuclear medicine and molecular imaging 20110401
New nucleoside analogs for patients with hematological malignancies. Expert opinion on investigational drugs 20110301
A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN hematology 20110101
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Advances in hematology 20110101
An update on the management of peripheral T-cell lymphoma and emerging treatment options. Journal of blood medicine 20110101
Rare tumors research in emerging countries. Rare tumors 20100930
Towards the development of a rapid, portable, surface enhanced Raman spectroscopy based cleaning verification system for the drug nelarabine. The Journal of pharmacy and pharmacology 20100901
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. British journal of haematology 20100801
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. American journal of hematology 20100801
New trends in nucleoside biotechnology. Acta naturae 20100701
A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Oncology reports 20100201
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC health services research 20100101
Use of clofarabine for acute childhood leukemia. Biologics : targets & therapy 20100101
Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? Journal of transplantation 20100101
Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia. Molecular cancer 20100101
Nelarabine in the treatment of refractory T-cell malignancies. Clinical Medicine Insights. Oncology 20100101
Application of new drugs in chronic lymphocytic leukemia. Mediterranean journal of hematology and infectious diseases 20100101
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 20091210
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematology/oncology clinics of North America 20091001
Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature. Leukemia research 20090701
Novel therapies for relapsed acute lymphoblastic leukemia. Current hematologic malignancy reports 20090701
Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. British journal of cancer 20090616
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules (Basel, Switzerland) 20090323
Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire international 20090201
[Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology 20090101
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. Drug design, development and therapy 20090101
Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. OncoTargets and therapy 20090101
Novel purine nucleoside analogues for hematological malignancies. Recent patents on anti-cancer drug discovery 20080601
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. The oncologist 20080601
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20080501
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network : JNCCN 20080401
Treating refractory leukemias in childhood, role of clofarabine. Therapeutics and clinical risk management 20080401
Phase I trial of nelarabine in indolent leukemias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301
Nelarabine. Drugs 20080101
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20080101
Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Current medicinal chemistry 20080101
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Seminars in oncology 20071201
Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies. Seminars in oncology 20071201
Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Therapeutics and clinical risk management 20071201
Nelarabine activity in acute biphenotypic leukemia. Leukemia research 20071101
Nelarabine: a novel purine antimetabolite antineoplastic agent. Clinical therapeutics 20070901
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 20070615
Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer chemotherapy and pharmacology 20070501
In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. British journal of haematology 20070401
New drugs 07, part I. Nursing 20070201
The long and winding road of the clinical development of Nelarabine. Leukemia & lymphoma 20070101
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leukemia & lymphoma 20070101
Treatment of acute lymphoblastic leukaemia : a new era. Drugs 20070101
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert opinion on investigational drugs 20061201
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale journal of biology and medicine 20061201
Clofarabine and nelarabine: two new purine nucleoside analogs. Current opinion in oncology 20061101
Milestones in oncology: introducing a new section. The oncologist 20061001
The legacy of great science: the work of Nobel Laureate Gertrude Elion lives on. The oncologist 20061001
[Glaxo Smith Kline. A large oncology pipeline]. Medizinische Monatsschrift fur Pharmazeuten 20061001
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 20060915
Nelarabine in the treatment of refractory T-cell malignant diseases. Expert opinion on pharmacotherapy 20060901
Nelarabine: a new purine analog in the treatment of hematologic malignancies. Reviews on recent clinical trials 20060901
Nelarabine: efficacy in the treatment of clinical malignancies. Future oncology (London, England) 20060801
Multifocal necrotizing leukoencephalopathy: An unusual complication of acute leukemia. Archives of neurology 20060701
Nelarabine use in leukemias. Drugs of today (Barcelona, Spain : 1998) 20060701
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20060601
Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents. Mini reviews in medicinal chemistry 20060501
Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia. The Medical letter on drugs and therapeutics 20060213
Nelarabine. Nature reviews. Drug discovery 20060101
New drug to treat rare leukemia and lymphoma. FDA consumer 20060101
New drugs: abatacept, sorafenib, and nelarabine. Journal of the American Pharmacists Association : JAPhA 20060101
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Current medicinal chemistry 20060101
Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Current cancer drug targets 20050901
Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. The Annals of pharmacotherapy 20050601
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520
Purine nucleoside antimetabolites in development for the treatment of cancer. Current opinion in investigational drugs (London, England : 2000) 20040601
New nucleoside analogs in the treatment of hematological disorders. Acta poloniae pharmaceutica 20040101
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20031101
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer research 20020601
CD4-CD8-'Double-negative' cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. The American journal of surgical pathology 20020201
Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 20011201
Nucleoside analogues in the treatment of haematological malignancies. Expert opinion on pharmacotherapy 20010601
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415
6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrobial agents and chemotherapy 19910501
Properties